Pembrolizumab Shows Promising Activity Against Head and Neck Cancer

A 132-patient study indicates that pembrolizumab immunotherapy is effective for patients with recurrent or metastatic head and neck cancer (HNC). The findings may fill a large unmet need for better treatments in this disease.
Overall, 57% of patients experienced some tumor shrinkage, and 24.8% had a marked decrease in tumor size known as partial or complete response. Pembrolizumab was active across a wide range of patient subgroups including those with HPV-positive and HPV-negative HNC.

Presented by Tanguy Seiwert, MD, University of Chicago, Chicago, IL at ASCO 2015, Chicago, IL

Year of Production:
Running Time:


Keywords: ,

Comments are closed.